IQVIA Holdings Inc. (NYSE:IQV) is a prominent player in the healthcare sector, specializing in contract research and providing data analytics services. On July 23, 2025, Cowen & Co. upgraded IQV's stock to a "Buy" rating, with the stock priced at $193.25 at the time. This upgrade reflects confidence in the company's financial performance and market position.
IQVIA's second-quarter 2025 results were impressive, with earnings per share (EPS) increasing by 6.4% year-over-year to $2.81. This exceeded the Zacks Consensus Estimate of $2.76, marking a +1.81% earnings surprise. The company has consistently outperformed EPS estimates over the past four quarters, showcasing its strong financial health.
The company's total revenues for the quarter reached $4 billion, surpassing the Zacks Consensus Estimate by 1.5%. This is an increase from the $3.81 billion reported in the same period last year. The Technology and Analytics segment contributed significantly, with an 8.9% revenue increase to $1.6 billion, while Contract Sales grew by 9.3% to $188 million.
Despite these positive results, IQVIA adjusted its 2025 guidance, raising its earnings per share and revenue outlook but reducing its adjusted EBITDA guidance. Year-to-date, IQVIA's stock has declined by 14.3%, which is less severe compared to the 30% decline in the industry it operates in. This contrasts with the 6.5% rise of the Zacks S&P 500 Composite.
IQVIA's stock is currently priced at $192.84, reflecting a 2.91% increase. The stock has fluctuated between $186.32 and $194.88 today, with a market capitalization of approximately $33.36 billion. The company's consistent performance and strong market position make it a noteworthy player in the healthcare sector.
